Perrigo Company plc (NYSE:PRGO – Get Free Report) has been given an average rating of “Hold” by the six analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $19.3333.
PRGO has been the topic of a number of recent research reports. Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th.
Read Our Latest Report on PRGO
Perrigo Trading Up 0.4%
Perrigo (NYSE:PRGO – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The company’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.06) EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts anticipate that Perrigo will post 2.18 EPS for the current fiscal year.
Perrigo Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be issued a $0.29 dividend. The ex-dividend date is Friday, August 28th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 8.0%. Perrigo’s payout ratio is presently -9.27%.
Key Headlines Impacting Perrigo
Here are the key news stories impacting Perrigo this week:
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $2.16 from $2.10, slightly narrowing the gap with the $2.20 consensus forecast. It also increased estimates for Q2 2028 EPS to $0.67 from $0.66 and Q4 2027 EPS to $0.84 from $0.72, suggesting some confidence in later-period earnings growth.
- Neutral Sentiment: Perrigo announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will meet with investors at the Barclays Global Consumer Conference on September 10. The event could provide updates on strategy and operating trends, but no new financial guidance was announced. Perrigo to Attend the Barclays Global Consumer Conference
- Negative Sentiment: Zacks cut its Q3 2026 EPS estimate to $0.59 from $0.64 and reduced Q4 2026 EPS to $0.64 from $0.72. Its FY2027 forecast fell to $2.29 from $2.50, while Q1 2027 EPS dropped to $0.47 from $0.60 and Q3 2027 EPS declined to $0.52 from $0.60.
- Negative Sentiment: Zacks also lowered Q1 2028 EPS to $0.49 from $0.70 and trimmed FY2028 EPS to $2.70 from $2.72. These reductions imply that analysts see weaker earnings momentum across several upcoming periods, which may limit further upside in PRGO despite the FY2026 and select later-quarter increases.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of PRGO. Corient Private Wealth LP raised its holdings in shares of Perrigo by 215.7% in the second quarter. Corient Private Wealth LP now owns 40,854 shares of the company’s stock valued at $424,000 after acquiring an additional 27,914 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Perrigo during the 2nd quarter valued at about $221,000. California State Teachers Retirement System increased its position in Perrigo by 911.0% during the 2nd quarter. California State Teachers Retirement System now owns 1,617,661 shares of the company’s stock valued at $155,694,000 after purchasing an additional 1,457,656 shares during the period. HB Wealth Management LLC bought a new stake in shares of Perrigo in the 2nd quarter valued at about $211,000. Finally, Odyssean LLC lifted its position in shares of Perrigo by 132.7% in the 2nd quarter. Odyssean LLC now owns 44,334 shares of the company’s stock worth $461,000 after purchasing an additional 25,282 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Recommended Stories
- Five stocks we like better than Perrigo
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
